

Martin A Walter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/711695/publications.pdf>

Version: 2024-02-01

90
papers

7,530
citations

66343

42
h-index

53230

85
g-index

95
all docs

95
docs citations

95
times ranked

8633
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. <i>Thyroid</i> , 2016, 26, 1343-1421.	4.5	1,757
2	Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [⁹⁰ Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 2416-2423.	1.6	571
3	The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 674-681.	6.4	334
4	FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1250-1269.	6.4	332
5	Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the <i>SDHC</i> Gene. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2057.	7.4	309
6	Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1045.	7.4	265
7	Distinguishing specific sexual and general emotional effects in fMRI Subcortical and cortical arousal during erotic picture viewing. <i>NeuroImage</i> , 2008, 40, 1482-1494.	4.2	191
8	Cohort Study of Somatostatin-Based Radiopeptide Therapy With [⁹⁰ Y-DOTA]-TOC Versus [⁹⁰ Y-DOTA]-TOC Plus [¹⁷⁷ Lu-DOTA]-TOC in Neuroendocrine Cancers. <i>Journal of Clinical Oncology</i> , 2012, 30, 1100-1106.	1.6	182
9	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.	6.4	182
10	Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. <i>Cancer Research</i> , 2009, 69, 3650-3656.	0.9	178
11	Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2007, 13, 6696-6702.	7.0	156
12	Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2007, 334, 514.	2.3	155
13	1,2,3-Triazoles as Amide Bond Mimics: Triazole Scan Yields Protease-Resistant Peptidomimetics for Tumor Targeting. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 8957-8960.	13.8	153
14	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes <i>SDHA</i> , <i>TMEM127</i> , <i>MAX</i> , and <i>SDHAF2</i> for Gene-Informed Prevention. <i>JAMA Oncology</i> , 2017, 3, 1204.	7.1	149
15	Correlation of 6- ¹⁸ F-Fluoro-l-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1532-1538.	5.0	141
16	Germline NF1 Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2784-2792.	3.6	126
17	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. <i>Human Mutation</i> , 2011, 32, 51-58.	2.5	117
18	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	3.1	114

#	ARTICLE	IF	CITATIONS
19	Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1938-1944.	3.6	112
20	¹⁸ F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas. <i>Journal of Nuclear Medicine</i> , 2009, 50, 513-519.	5.0	90
21	Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1868-1877.	6.4	87
22	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. <i>BMJ</i> , The, 2014, 349, g4539-g4539.	6.0	74
23	Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 1136-45.	7.0	73
24	Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 214-222.	6.4	69
25	On transcending the impasse of respiratory motion correction applications in routine clinical imaging - a consideration of a fully automated data driven motion control framework. <i>EJNMMI Physics</i> , 2014, 1, 8.	2.7	68
26	Influence of Different Spacers on the Biological Profile of a DOTA-Somatostatin Analogue. <i>Bioconjugate Chemistry</i> , 2007, 18, 84-92.	3.6	67
27	[18F]Fluorodeoxyglucose PET in Large Vessel Vasculitis. <i>Radiologic Clinics of North America</i> , 2007, 45, 735-744.	1.8	67
28	Therapeutic Options for Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2019, 5, 480.	7.1	67
29	Evaluation of [99mTc/EDDA/HYNIC]octreotide derivatives compared with [111In-DOTA0,Tyr3,Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1561-9.	5.0	66
30	Somatostatin Receptor-Targeted Radiopeptide Therapy with ⁹⁰ Y-DOTATOC and ¹⁷⁷ Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2015, 56, 171-176.	5.0	63
31	The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1620-1625.	5.0	60
32	Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2847-2852.	7.1	54
33	Upregulation of Key Molecules for Targeted Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1805-1810.	5.0	54
34	The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 468-475.	6.4	52
35	Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. <i>Cancer</i> , 2010, 116, 31-40.	4.1	49
36	Impact of 3,4-Dihydroxy-6-18F-Fluoro-L-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective. <i>Journal of Nuclear Medicine</i> , 2012, 53, 393-398.	5.0	49

#	ARTICLE	IF	CITATIONS
37	Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 730-737.	6.4	47
38	Planning and reporting of quality-of-life outcomes in cancer trials. <i>Annals of Oncology</i> , 2015, 26, 1966-1973.	1.2	47
39	[⁹⁰ Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer. <i>Cancer</i> , 2009, 115, 2052-2062.	4.1	46
40	Completion and Publication Rates of Randomized Controlled Trials in Surgery. <i>Annals of Surgery</i> , 2015, 262, 68-73.	4.2	45
41	Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. <i>European Journal of Clinical Investigation</i> , 2004, 34, 365-370.	3.4	44
42	Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. <i>Cancer</i> , 2011, 117, 1377-1385.	4.1	43
43	Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 909-918.	2.1	43
44	^{99m} Tc-DPD-SPECT/CT predicts the outcome of imaging-guided diagnostic anaesthetic injections: A prospective cohort study. <i>European Journal of Radiology</i> , 2011, 80, e410-e415.	2.6	41
45	Indium-111 labeled gold nanoparticles for in-vivo molecular targeting. <i>Biomaterials</i> , 2014, 35, 7050-7057.	11.4	41
46	Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. <i>Journal of Nuclear Medicine</i> , 2021, 62, 507-513.	5.0	37
47	Is There a Need for Dedicated Bone Imaging in Addition to ¹⁸ F-FDG PET/CT Imaging in Pediatric Sarcoma Patients?. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 131-136.	0.6	33
48	Learning from failure - rationale and design for a study about discontinuation of randomized trials (DISCO study). <i>BMC Medical Research Methodology</i> , 2012, 12, 131.	3.1	33
49	Impact of Screening Kindreds for SDHD p.Cys11X as a Common Mutation Associated with Paraganglioma Syndrome Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4818-4825.	3.6	28
50	Premature Discontinuation of Randomized Trials in Critical and Emergency Care. <i>Critical Care Medicine</i> , 2016, 44, 130-137.	0.9	28
51	Somatostatin-based radiotherapy with [⁹⁰ Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. <i>Journal of Translational Medicine</i> , 2013, 11, 17.	4.4	24
52	Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study. <i>Journal of Pediatrics</i> , 2017, 184, 209-214.e1.	1.8	23
53	Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. <i>PLoS Medicine</i> , 2016, 13, e1002046.	8.4	20
54	[¹⁸ F]FDG-PET of giant-cell aortitis. <i>Rheumatology</i> , 2005, 44, 690-691.	1.9	19

#	ARTICLE	IF	CITATIONS
55	An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. <i>Journal of Clinical Epidemiology</i> , 2016, 69, 152-160.	5.0	19
56	Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 46-55.	1.0	15
57	Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules. <i>Gland Surgery</i> , 2019, 8, S118-S125.	1.1	14
58	¹⁸ F-FluoroDeoxyGlucose Uptake of Bone and Soft Tissue Sarcomas in Pediatric Patients. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 579-587.	0.8	13
59	Metabolic Imaging Allows Early Prediction of Response to Vandetanib. <i>Journal of Nuclear Medicine</i> , 2011, 52, 231-240.	5.0	13
60	Towards tailored radiopeptide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1231-1237.	6.4	12
61	Different strategies to overcome the effect of carbimazole on high and low dose radioiodine therapy: results from continuous dose effect models. <i>European Journal of Clinical Investigation</i> , 2009, 39, 51-57.	3.4	11
62	Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in Trp53 ^{+/+} Mice. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1285-1292.	5.0	11
63	Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison. <i>Nuklearmedizin - NuclearMedicine</i> , 2005, 44, 33-6.	0.7	11
64	Extraction of high-integrity RNA suitable for microarray gene expression analysis from long-term stored human thyroid tissues. <i>Pathology</i> , 2006, 38, 249-253.	0.6	9
65	Graves' Disease. <i>New England Journal of Medicine</i> , 2008, 359, 1407-1409.	27.0	7
66	Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2017, 58, 97-102.	5.0	7
67	MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 917-923.	5.0	7
68	Variations in radioiodine ablation: decision-making after total thyroidectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 554-560.	6.4	7
69	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013700.	2.8	7
70	Association of Surgical Volume and Quality Management in Thyroid Surgery: A Two-Nation Multicenter Study. <i>World Journal of Surgery</i> , 2019, 43, 2218-2227.	1.6	6
71	Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 159-168.	1.0	6
72	Coregistered Iodine-131 Single Photon Emission Computed Tomography/Computed Tomography Reveals Dedifferentiation in a Metastatic Follicular Thyroid Carcinoma. <i>Thyroid</i> , 2006, 16, 1063-1064.	4.5	5

#	ARTICLE	IF	CITATIONS
73	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. <i>BMJ</i> , The, 2014, 349, g4921-g4921.	6.0	5
74	Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study design. <i>Trials</i> , 2013, 14, 335.	1.6	4
75	¹⁸ F-RB390: Innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). <i>Prostate</i> , 2015, 75, 348-359.	2.3	3
76	The Role of Positron Emission Tomographyâ€“Computed Tomography in the Workup of Nonâ€“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e1915873.	5.9	2
77	Situs inversus completus. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1202-1202.	6.4	1
78	The detrimental effect of anti-thyroid drugs on the outcome of radioiodine therapy is not directly due to decreased radioiodine uptake. <i>Nuclear Medicine Communications</i> , 2005, 26, 70.	1.1	1
79	[¹⁸ F]Fluorodeoxyglucose PET in Large Vessel Vasculitis. <i>PET Clinics</i> , 2006, 1, 179-189.	3.0	1
80	Reply: 18F-FDG PET in Planning Radiation Treatment of Non Small Cell Lung Cancer: Where Exactly Is the Tumor?. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1403-1403.	5.0	1
81	The Influence of Different Metal-Chelators on the Biological Profile of Nanoparticles for Gallium-68 Based Molecular Imaging. <i>Journal of Nano Research</i> , 2012, 20, 21-31.	0.8	1
82	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	2.8	1
83	Enhancement of radioiodine uptake in hyperthyroidism by administration of hydrochlorothiazide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 474-474.	6.4	0
84	Antithyroid Drugs and Radioiodine and the Absence of Evidence. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1403a-1403a.	5.0	0
85	Research update for articles published in <i>EJCI</i> in 2009. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1149-1163.	3.4	0
86	Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs. <i>Medical Radiology</i> , 2012, , 323-332.	0.1	0
87	Reply: Somatostatin Receptorâ€“Targeted Radiopeptide Therapy in Patients with Progressive Unresectable Meningioma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1657.2-1658.	5.0	0
88	Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic Issues. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1532.1-1532.	5.0	0
89	Intra-vagal parathyroid adenoma on digital PET/CT with ¹⁸ F-fluorocholine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4521-4522.	6.4	0
90	Radioactive Therapy and External Radiotherapy of Thyroid Cancer. , 2012, , 313-326.		0